hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06353828, orgStudyIdInfo id: ICBD-UC-01, briefTitle: Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: CannaMore Biotechs, class: INDUSTRY, descriptionModule briefSummary: Ulcerative proctitis can lead to considerable morbidity, and the available treatment options are limited. Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic animal models of inflammation, including IBD models.Based on positive safety and initial efficacy profiles of CBD found in IBD animal and clinical studies, the main aim of this study is to evaluate the safety, tolerability and efficacy of a novel enema formulation of CBD for the treatment of active ulcerative proctitis., conditionsModule conditions: Ulcerative Colitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: CBD, synthetic form, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change from baseline in Full Mayo Score, secondaryOutcomes measure: Change in Partial Mayo Score, secondaryOutcomes measure: Change in patient reported outcome (PRO-UC), secondaryOutcomes measure: Change in endoscopic Mayo subscore in distal 15 cm of anus, secondaryOutcomes measure: Change in the length of the inflamed colon, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Meir Medical Center, city: Kfar Saba, country: Israel, geoPoint lat: 32.175, lon: 34.90694, hasResults: False
protocolSection identificationModule nctId: NCT06353815, orgStudyIdInfo id: anaesthetic efficacy, briefTitle: Clinical Evaluation of Anaesthetic Efficacy of 4% Articaine Buccal Infiltration Versus Inferior Alveolar Nerve Block, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Clinical evaluation of anaesthetic efficacy of 4% articaine buccal infiltration versus inferior alveolar nerve block during restorative dental treatment in mandibular first permanent molars, conditionsModule conditions: Restorative Dental Treatment by Buccal Infiltration Anaesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: 4% articaine infiltration, outcomesModule primaryOutcomes measure: Success of local anesthesia, secondaryOutcomes measure: Child behavior during treatment, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 9 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353802, orgStudyIdInfo id: P.T.REC/012/004963, briefTitle: Relationship Between Chronic Non-Specific Neck Pain And Lumbar Reposition Sense, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: to investigate the correlation between chronic non-specific neck pain and lumbar reposition sense., conditionsModule conditions: Chronic Non-specific Neck Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 67, type: ACTUAL, armsInterventionsModule interventions name: Chronic non-specific neck pain and lumbar reposition sense, outcomesModule primaryOutcomes measure: Correlation Between Chronic Non-Specific Neck Pain And Lumbar Reposition Sense Using iPhone inclinometer app, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Physical Therapy College Cairo University, city: Giza, zip: 12613, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06353789, orgStudyIdInfo id: RoADPain Clinical Study, briefTitle: Adolescent Dysmenorrhoea as a Risk Factor for Chronic Pain: Clinical Cohort Study, acronym: RoADPain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Oxford, class: OTHER, collaborators name: University of Exeter, collaborators name: University of York, collaborators name: Endometriosis UK, descriptionModule briefSummary: This study aims to understand whether changes in a variety of body systems which are seen in adult women with period pain are also seen in adolescents in the first few years of having periods. This information will help us to understand 1) how quickly any changes occur, informing clinical practice, and 2) how period pain might lead to other types of chronic pain, potentially allowing development of preventative strategies., conditionsModule conditions: Dysmenorrhea, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 132, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Quantitative Sensory Testing (QST), primaryOutcomes measure: Heart rate (HR), primaryOutcomes measure: Change in heart rate, primaryOutcomes measure: Bladder sensitivity to filling, primaryOutcomes measure: Volume voided at maximum tolerance, primaryOutcomes measure: Pain Catastrophising: Pain Catastrophising Scale (PCS) (Sullivan), primaryOutcomes measure: Area under the curve (AUC) of single day salivary cortisol profile, secondaryOutcomes measure: Change of pressure pain threshold (PPT), secondaryOutcomes measure: fMRI scan, eligibilityModule sex: FEMALE, minimumAge: 11 Years, maximumAge: 20 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353776, orgStudyIdInfo id: 02052023, briefTitle: MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-03, primaryCompletionDateStruct date: 2023-10-31, completionDateStruct date: 2023-10-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University Tunis El Manar, class: OTHER, descriptionModule briefSummary: MicroPulse transscleral laser therapy (TLT) is proven to be effective in reducing intraocular pressure with minimal complications in either primary or secondary glaucoma. However, its impact on the human ocular surface remains unexplored. This study aims to bridge this gap by examining the clinical and histopathological effects of MicroPulse TLT on the ocular surface., conditionsModule conditions: Conjunctiva, conditions: Cornea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: conjunctival biopsy after micropulse transscleral laser therapy, outcomesModule primaryOutcomes measure: conjunctival inflammation or fibrosis, primaryOutcomes measure: intraocular pression, primaryOutcomes measure: ocular surface disease index score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mohamed Taher Maamouri Hospital, city: Nabeul, zip: 8000, country: Tunisia, geoPoint lat: 36.45606, lon: 10.73763, hasResults: False
protocolSection identificationModule nctId: NCT06353763, orgStudyIdInfo id: CV, briefTitle: Design, Implementation, and Evaluation of Virtual Reality in the Nursing Curriculum, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-02-24, primaryCompletionDateStruct date: 2022-05-30, completionDateStruct date: 2022-06-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Clinica Universidad de Navarra, Universidad de Navarra, class: OTHER, descriptionModule briefSummary: The aim of the study is to determine the effectiveness of an immersive virtual reality learning programme for nursing students, based on virtual glasses, in acquiring the competence (knowledge, skills and attitudes) to care for patients with pressure ulcers, and to compare it with the traditional teaching method.The design was an exploratory randomised controlled trial. The variables used to measure effectiveness were competence and its attributes: knowledge assessment by a multiple-choice test (Pressure Ulcer Knowledge Assessment Tool, Pukat 2.0 instrument), skill performance by direct observation of procedural skills (simulated cases with standardised patients) and satisfaction and usability assessment (Usefulness, Satisfaction and Ease of Use Questionnaire)., conditionsModule conditions: Pressure Ulcer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: Participants were blinded in their group assignment., whoMasked: PARTICIPANT, enrollmentInfo count: 127, type: ACTUAL, armsInterventionsModule interventions name: Immersive virtual reality learning program, outcomesModule primaryOutcomes measure: Knowledge, primaryOutcomes measure: Skill performance, primaryOutcomes measure: Usefulness, Satisfaction, and Ease of Use, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Navarra, city: Pamplona, state: Navarra, country: Spain, geoPoint lat: 42.81687, lon: -1.64323, hasResults: False
protocolSection identificationModule nctId: NCT06353750, orgStudyIdInfo id: 331039, briefTitle: Intracellular Magnesium and Heart Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2026-04-25, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: University of Oxford, class: OTHER, collaborators name: British Heart Foundation, collaborators name: Oxford University Hospitals NHS Trust, descriptionModule briefSummary: Low magnesium levels are surprisingly common in those with a heart condition known as HFpEF, where the heart pumps well but is too rigid to fill properly with blood. While routine blood tests can check magnesium levels, they don't tell us how much magnesium is actually inside the heart and muscle cells, where it's vital for energy and overall function. Our research aims to get a clearer picture by looking directly at the magnesium inside these cells and understanding its role in the body's energy production and usage. We're also interested in how magnesium levels affect symptoms and the body's handling of sugar. We're using advanced medical imaging techniques, like heart magnetic resonance imaging (MRI) and other heart and muscle function tests, at rest and when the heart is working hard to help answer these questions. We'll compare the magnesium levels inside the cells before and after giving a supplement of magnesium to see if this can make a difference in how the heart and muscles work., conditionsModule conditions: Heart Failure With Preserved Ejection Fraction, conditions: Hypomagnesemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: Magnesium supplement, outcomesModule primaryOutcomes measure: Myocardial/ skeletal muscle metabolism and energetics at rest and stress., secondaryOutcomes measure: Serum versus intracellular magnesium concentration, secondaryOutcomes measure: Cardiac function, secondaryOutcomes measure: Skeletal muscle performance, secondaryOutcomes measure: Symptoms, secondaryOutcomes measure: Insulin sensitivity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Oxford Centre for Magnetic Resonance (OCMR), city: Oxford, zip: OX3 9DU, country: United Kingdom, contacts name: Jennifer L Holland, BMBS, role: CONTACT, email: jennifer.holland@wolfson.ox.ac.uk, contacts name: Oliver Rider, BM BCh, role: CONTACT, email: oliver.rider@cardiov.ox.ac.uk, geoPoint lat: 51.75222, lon: -1.25596, hasResults: False
protocolSection identificationModule nctId: NCT06353737, orgStudyIdInfo id: CTO 4489, briefTitle: Looking for Asymptomatic Mpox in a Population at High Risk, acronym: LAMP, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Unity Health Toronto, class: OTHER, descriptionModule briefSummary: Mpox is caused by a virus that can be spread through touching the affected skin of someone who has the infection, touching sheets or clothes that has been used by someone with the infection, or breathing in particles of virus from someone who has the infection. Mpox infection can cause skin and flu-like symptoms, but can also cause very few symptoms, or no symptoms at all. While the number of participants with mpox symptoms can be tracked, little is known about how many people have mpox, but experience few or no symptoms at all. To do this, a Canadian sample of gay, bisexual and other men who have sex with men (GBMSM) who are participating in a randomized controlled trial will be screened for mpox symptoms. Screening will include questions about whether they may be experiencing any mpox symptoms, history of past diagnosis of mpox, sexual history, and vaccination history and awareness. Swabs will be taken to test for the presence of mpox virus, and a blood sample will be taken to test for antibodies. Approximately 450 individuals will be recruited. The results will be descriptive in nature., conditionsModule conditions: Mpox (Monkeypox), designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 450, type: ESTIMATED, outcomesModule primaryOutcomes measure: Asymptomatic prevalence, secondaryOutcomes measure: Symptomatic prevalence, secondaryOutcomes measure: Mpox seropositivity, secondaryOutcomes measure: Characteristics, secondaryOutcomes measure: Characteristics of seropositivity, eligibilityModule sex: MALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unity Health Toronto, status: RECRUITING, city: Toronto, state: Ontario, zip: M5B 1T8, country: Canada, contacts name: Reva Persaud, role: CONTACT, phone: 416-360-4000, phoneExt: 77105, email: reva.persaud@unityhealth.to, contacts name: Darrell HS Tan, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06353724, orgStudyIdInfo id: RP2218, briefTitle: Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent, acronym: stent, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-10-14, primaryCompletionDateStruct date: 2020-10-01, completionDateStruct date: 2021-01-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare between the Effect of Using Conventional and Digital Oral Positional Radiation Stent on Healthy tissues, salivary PH. The main question it aims to answer are: Does the difference in manufacturing method affect on Healthy tissues, salivary PH.Participants will use radiation positioning stent during radiotherapy sessions Two groups will be compared* Group A: OPRS was constructed according to the conventional technique.* Group B: OPRS was constructed digitally using CAD /CAM technology. to evaluate Dosimetric analysis to quantify the radiation dose in OARs, PH of saliva measurement and Mucositis assessment., conditionsModule conditions: Radiotherapy Side Effect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule interventions name: conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning, interventions name: Digital positioning stent, outcomesModule primaryOutcomes measure: Dosimetric analysis, primaryOutcomes measure: PH of saliva measurement:, primaryOutcomes measure: Mucositis assessment:, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, city: Tanta, state: Gharbia, zip: 31527, country: Egypt, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06353698, orgStudyIdInfo id: Nnftri, briefTitle: Fasting Mimicking Diet With Chemotherapy in Patients With Leukemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-02, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: National Nutrition and Food Technology Institute, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to investigate The effect of fasting mimicking diet with chemotherapy on the number of blasts and platelets and quality of life in patients with acute lymphoid leukemia and acute myeloid leukemia., conditionsModule conditions: Fasting Mimicking Diet, conditions: Leukemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: fasting mimicking diet, outcomesModule primaryOutcomes measure: Blast cell count, primaryOutcomes measure: Quality of life, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azita Hekmatdoost, status: RECRUITING, city: Tehran, state: Middle East, zip: 19835, country: Iran, Islamic Republic of, contacts name: Azita Hekmatdoost, MD, PhD, role: CONTACT, phone: +989123065084, email: a_hekmat2000@yahoo.com, geoPoint lat: 35.69439, lon: 51.42151, locations facility: Ehsan Hejazi, status: RECRUITING, city: Tehran, zip: 19839-63113, country: Iran, Islamic Republic of, contacts name: Ehsan Hejazi, PhD, role: CONTACT, phone: 00989121530775, email: ehsanhejazi@sbmu.ac.ir, geoPoint lat: 35.69439, lon: 51.42151, hasResults: False
protocolSection identificationModule nctId: NCT06353685, orgStudyIdInfo id: neo-CHART-HNC, briefTitle: De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: The prognosis of locally advanced oral squamous cell carcinoma(OSCC ) is poor, and there are still many problems to be solved in the current treatment paradigm. Neoadjuvant chemotherapy combined with immunotherapy can significantly improve the pCR and MPR rates in patients with locally advanced OSCC. For patients who achieve pCR and MPR after neoadjuvant therapy and surgery, it is still hotly debated regarding whether to implement postoperative de-escalation radiotherapy. Neoadjuvant therapy is an ideal predictor of radiosensitivity. In theory, neoadjuvant therapy can eliminate microscopic lesions, thereby reducing the dose and volume of irradiation.Continuous hyperfractionated accelerated radiotherapy (CHART, based on hyperfractionated radiotherapy, increasing daily or weekly treatments and shortening the total treatment duration, but reducing the total dose), is to give a higher dose of radiation to tumor tissue in a shorter period of time, so as to overcome the accelerated reproliferation and inhibit the repair of sublethal damage of tumor cells. It is beneficial to improve the local control rate of tumor, control the acute injury of normal tissue and the yield acceptable late treatment-related complications. The specific protocol was as follows: high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total, fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks., conditionsModule conditions: De-escalated Radiotherapy; Head and Neck Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 103, type: ESTIMATED, armsInterventionsModule interventions name: Continuous, hyperfractionated, accelerated radiotherapy(CHART), outcomesModule primaryOutcomes measure: 2-year PFS, secondaryOutcomes measure: 2-year OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False